Loading...
Market
Which company will be the next major competitor to release a new treatment for PD-L1 positive advanced NSCLC by end of 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Official announcements from pharmaceutical companies and clinical trial registries
Story
Summit Therapeutics' Ivonescimab Shows PFS of 11.14 Months, Outperforms Merck's Keytruda in PD-L1 Positive Lung Cancer Trial
Sep 8, 2024, 03:30 PM
At the 2024 World Conference on Lung Cancer (WCLC) in San Diego, Summit Therapeutics presented groundbreaking data from their Phase 3 HARMONi-2 trial. The trial revealed that ivonescimab, an investigational therapy, significantly outperformed Merck's Keytruda in treating patients with PD-L1 positive advanced non-small cell lung cancer (NSCLC). Ivonescimab demonstrated a median progression-free survival (PFS) of 11.14 months compared to 5.82 months for Keytruda, reducing the risk of disease progression or death by 49% (HR=0.51, p<0.0001). The objective response rate (ORR) was 50% for ivonescimab versus 38.5% for Keytruda. This data marks a historic achievement in the field of lung cancer treatment, potentially setting a new standard of care.
View original story
Similar markets
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%
Merck • 25%
Roche • 25%
Another Pharmaceutical Company • 25%
No clear dominator • 25%
iTeos Therapeutics • 25%
GSK • 25%
Another company • 25%
No approval by end of 2025 • 25%
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Merck • 25%
Bristol-Myers Squibb • 25%
Roche • 25%
Other • 25%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Novartis • 25%
Roche • 25%
Other • 25%